Fig. 3: CSL311 improves SpO2 levels by reducing lung inflammation and injury. | Cell Death & Disease

Fig. 3: CSL311 improves SpO2 levels by reducing lung inflammation and injury.

From: Blocking the human common beta subunit of the GM-CSF, IL-5 and IL-3 receptors markedly reduces hyperinflammation in ARDS models

Fig. 3

A Blood oxygenation was monitored in hβcTg mice across multiple timepoints using a MouseSTAT® Jr. Pulse Oximeter, where a single dose of CSL311 significantly improved SpO2 levels that were markedly reduced as a consequence of lung injury caused by LPS challenge. B Representative H&E stained lung sections demonstrate that LPS (10 μg at 24-hours) causes inflammation around the vasculature, bronchiole and alveoli. C Inflammation was blindly scored, demonstrating that lung injury was significantly reduced with CSL311 treatment. D CSL311 treatment also significantly reduced oedema as assessed by quantifying total protein levels in BAL-fluid. n = 5–10; data are Mean ± SE; *p < 0.05, **p < 0.005, ****p < 0.0001 ANOVA.

Back to article page